从芬戈莫德到抗 CD20 治疗的短洗脱期是安全的，并降低了再激活的风险。
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
机构信息
Department of Neurology, centre de ressources et de compétences SEP - Paris, Pitié-Salpêtrière University Hospital, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris, France.
Paris-Brain Institute (ICM), Paris Brain Institute's Data and Analysis Core, Pitié-Salpêtrière Hospital, Sorbonne université, Inserm U1127, CNRS UMR 7225, Paris, France.
出版信息
Rev Neurol (Paris). 2023 Nov;179(9):1035-1038. doi: 10.1016/j.neurol.2023.03.028. Epub 2023 Aug 24.
The frequency of switches between Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) has increased considerably over previous years. Between fingolimod and anti-CD20 therapies, a 1-month washout period is usually recommended. However, disease reactivations are frequent after fingolimod (Fg) cessation. Using a retrospective observational monocentric exposed/non-exposed cohort study, we investigated the efficacy and the safety of a shorter washout period (WP) between Fg and anti-CD20. We compared two groups: 25 patients with a short WP (<21 days) and 20 patients with a longer WP (>21 days). We observed no reactivation during WP in patients with a short WP against a relapse in 55% of patients in the longer group. Moreover, clinical and biological safety was excellent. Based on these findings, we recommend a shorter WP between fingolimod and anti-CD20 therapies in MS.
多发性硬化症（MS）中疾病修正疗法（DMT）的转换频率近年来显著增加。在 fingolimod 和抗 CD20 治疗之间，通常推荐 1 个月的洗脱期。然而，fingolimod（Fg）停药后疾病常会复发。采用回顾性观察性单中心暴露/非暴露队列研究，我们研究了 Fg 和抗 CD20 之间更短洗脱期（WP）的疗效和安全性。我们比较了两组：25 例 WP 较短（<21 天）和 20 例 WP 较长（>21 天）的患者。在 WP 期间，WP 较短的患者中没有出现复发，而 WP 较长的患者中有 55%出现复发。此外，临床和生物学安全性极佳。基于这些发现，我们建议在 MS 中缩短 fingolimod 和抗 CD20 治疗之间的 WP。
Zotero 插件